Using haemoadsorption during heart transplantation
Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
NA · Medical University of Vienna · NCT05270902
This study is testing if using a treatment called haemoadsorption during heart transplantation can help reduce inflammation and improve recovery outcomes for patients in the days following their surgery.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna (other) |
| Drugs / interventions | tocilizumab |
| Locations | 1 site (Vienna, State of Vienna) |
| Trial ID | NCT05270902 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation. It aims to assess how HA influences circulating cytokine levels and the inflammatory response in the first 120 hours post-transplant. Additionally, the study will evaluate the impact of HA on various postoperative outcomes, including primary graft dysfunction, cerebral dysfunction, fluid accumulation, renal dysfunction, mechanical ventilation duration, ICU stay, and 30-day mortality.
Who should consider this trial
Good fit: Ideal candidates are adult patients undergoing heart transplantation.
Not a fit: Patients under 18 years old or those receiving specific immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved postoperative outcomes and reduced complications for heart transplant patients.
How similar studies have performed: While the use of haemoadsorption in other contexts has shown promise, this specific application during heart transplantation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients undergoing heart transplantation Exclusion Criteria: * Declined informed consent * Age \< 18 years# * Receiving antileukocyte drugs * Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab) * DCD * Ex-vivo perfusion
Where this trial is running
Vienna, State of Vienna
- Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna — Vienna, State of Vienna, Austria (RECRUITING)
Study contacts
- Principal investigator: Martin H. Bernardi, MD, PhD — Medical University of Vienna
- Study coordinator: Martin H. Bernardi, MD, PhD
- Email: martin.bernardi@meduniwien.ac.at
- Phone: 0043140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Heart Transplantation, Cytosorb